Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BioTime Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 16
Venture Financing 18
AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19
Partnerships 20
BioTime and Hepregen Form Joint Venture 20
Licensing Agreements 21
Processa Pharma Enters into Licensing Agreement with BioTime 21
BioTime Enters into Licensing Agreement with Hadassah Medical 22
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30
Equity Offering 31
BioTime Completes Public Offering of Shares for USD28.8 Million 31
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33
BioTime to Raise up to USD25 Million in Private Placement of Shares 35
BioTime Raises USD20 Million in Public Offering of Shares 36
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 38
BioTime Raises USD5 Million in Private Placement of Shares 40
BioTime Raises USD20.4 Million in Private Placement of Shares 41
BioTime Raises USD8.6 Million in Private Placement of Shares 43
BioTime Raises USD29 Million in Private Placement of Shares 44
BioTime Completes Private Placement Of Shares For US$6.4 Million 46
BioTime Announces Public Offering Of Shares For Up To US$15 Million 47
BioTime Completes Public Offering Of Shares For US$3.5 Million 48
BioTime Completes Private Placement Of Units For US$9 Million 49
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 50
BioTime Announces Private Placement Of Common Stock 52
Acquisition 53
BioIVT Acquires Ascendance Biotech 53
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 54
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 56
BioTime Inc – Key Competitors 58
BioTime Inc – Key Employees 59
BioTime Inc – Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Joint Venture 61
Recent Developments 62
Strategy And Business Planning 62
Apr 06, 2017: BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging 62
Financial Announcements 63
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 63
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 65
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 67
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 69
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 71
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 73
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 75
Corporate Communications 78
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 78
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 79
Government and Public Interest 80
Jun 29, 2018: BioTime Awarded Grant from the National Institutes of Health 80
Jun 29, 2018: BioTime Awarded Grant From the NIH (National Institutes of Health) 81
May 02, 2018: AgeX Announces NIH Grant Award 82
Sep 18, 2017: BioTime Awarded Grant from the NIH 83
Product News 84
Jan 02, 2018: AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer 84
Other Significant Developments 85
Jun 19, 2017: Biotime Expands & Advances Ophthalmology Portfolio 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86
BioTime Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 16
AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19
BioTime and Hepregen Form Joint Venture 20
Processa Pharma Enters into Licensing Agreement with BioTime 21
BioTime Enters into Licensing Agreement with Hadassah Medical 22
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30
BioTime Completes Public Offering of Shares for USD28.8 Million 31
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33
BioTime to Raise up to USD25 Million in Private Placement of Shares 35
BioTime Raises USD20 Million in Public Offering of Shares 36
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 38
BioTime Raises USD5 Million in Private Placement of Shares 40
BioTime Raises USD20.4 Million in Private Placement of Shares 41
BioTime Raises USD8.6 Million in Private Placement of Shares 43
BioTime Raises USD29 Million in Private Placement of Shares 44
BioTime Completes Private Placement Of Shares For US$6.4 Million 46
BioTime Announces Public Offering Of Shares For Up To US$15 Million 47
BioTime Completes Public Offering Of Shares For US$3.5 Million 48
BioTime Completes Private Placement Of Units For US$9 Million 49
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 50
BioTime Announces Private Placement Of Common Stock 52
BioIVT Acquires Ascendance Biotech 53
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 54
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 56
BioTime Inc, Key Competitors 58
BioTime Inc, Key Employees 59
BioTime Inc, Subsidiaries 60
BioTime Inc, Joint Venture 61
List of Figures
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11